(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The hunt for dark matter: a trivia quiz - 2Orbán orders stop to gas deliveries to Ukraine via Hungary from July
- 3Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- 4Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
- 5Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Remain Cool and Solid: Top Summer Food sources for 2024
- Jersey's wellbeing score is below UK and France
- 4 astronauts are now on their path to the moon. Here’s what happens next
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Oil, energy and food: Which countries in Europe are most exposed to higher food prices?
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- The 10 Most Significant Virtual Entertainment Missions
- As Western heat wave ends, scientists try to make sense of its length and intensity
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
